Clinical trials: Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
Pediatric Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL), Ph+ Mixed Phenotype Acute Leukemia (MPAL)
A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
This study is about an anticancer drug called ponatinib which is a tyrosine kinase inhibitor given with chemotherapy to children, teenagers, and young adults up to 21 years of age with Philadelphia Chromosome-Positive Acute…
- Conditions
- Pediatric Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL), Ph+ Mixed Phenotype Acute Leukemia (MPAL), Philadelphia Chromosome-Like ALL (Ph-like ALL)
- Trial name
- NCT04501614
- Testing
- Ponatinib, Chemotherapy Agents
- Where
- 64 sites in United States, Argentina and 13 more
- Volunteers
- 11 people
- Sponsor
- Takeda
Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia
Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
This randomized phase III trial studies how well imatinib mesylate works in combination with two different chemotherapy regimens in treating patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic…
- Conditions
- Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia, T Acute Lymphoblastic Leukemia
- Trial name
- NCT03007147
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Calaspargase Pegol, Cyclophosphamide
- Where
- 226 sites in United States, Australia and 17 more
- Volunteers
- 352 people
- Sponsor
- Children's Oncology Group
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
An Extension Study to Determine the Efficacy and Safety of STI571 in Participants With Chronic Myeloid Leukemia Who Are Refractory to or Intolerant of Interferon-Alpha
During the Core Phase of the study, participants received STI571 at a dose of 400 milligrams (mg) daily for up to 12 months. Participants completing 12 months of therapy were eligible to continue treatment in the Extension Phase…
- Trial name
- NCT00171223
- Testing
- STI571
- Where
- 28 sites in United States, France and 4 more
- Volunteers
- 532 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia
Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALL
The purpose of this study is to further assess the safety of dasatinib in imatinib intolerant or resistant patients with chronic phase chronic myeloid leukemia, advanced phase chronic myeloid leukemia or Philadelphia chromosome…
- Trial name
- NCT00349518
- Testing
- Dasatinib
- Where
- 20 sites in Hungary, Italy and 4 more
- Sponsor
- Bristol-Myers Squibb
Healthy (For Part A), Chronic Myeloid Leukemia (for Part B and C)
Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies
Phase 1/2 study to determine safety, tolerability, pharmacokinetics, and anti-leukemic activity of Vodobatinib (K0706) in treatment-refractory/intolerant CML
- Trial name
- NCT02629692
- Testing
- Vodobatinib (K0706) capsules
- Where
- 35 sites in United States, Belgium and 8 more
- Volunteers
- 124 people
- Sponsor
- Sun Pharma Advanced Research Company Limited
CD19 Positive, Philadelphia Chromosome Positive
Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic Leukemia
This phase I/II studies the side effects of pembrolizumab and blinatumomab and to see how well they work in treating participants with acute lymphoblastic leukemia that has come back or has not responded to the treatment.
- Conditions
- CD19 Positive, Philadelphia Chromosome Positive, Recurrent Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia
- Trial name
- NCT03512405
- Testing
- Blinatumomab, Laboratory Biomarker Analysis, Pembrolizumab
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- City of Hope Medical Center
Philadelphia Positive Acute Lymphoblastic Leukemia
Study of Frontline Dasatinib Plus Chemotherapy in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (PH+ALL)
The current standard treatment approach for young patients with Positive Acute Lymphoblastic Leukemia (Ph+ALL) is the combination of a chemotherapy protocol employing four to five cytotoxic agents typically used for ALL together…
- Trial name
- NCT01724879
- Testing
- Dasatinib
- Where
- 22 sites in Germany
- Volunteers
- 19 people
- Sponsor
- Goethe University
Acute Lymphobkastic Leukemia, Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Evaluation of the Efficacy of Ponatinib in Ph+ ALL in the Real-world
The goal of this retrospective observational study is to learn about the efficacy of ponatinib in Philadelphia-positive ALL (Ph+ ALL) patients in a real-world setting.
- Trial name
- PONA4ALL Ph+ (NCT07356960)
- Volunteers
- 103 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Ph+ ALL, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)
A global multicenter, open-label, randomized and registrational Phase 3 study to evaluate efficacy and safety of olverembatinib combined with chemotherapy versus investigator's choice of tyrosine kinase inhibitor (TKI) combined…
- Trial name
- NCT06051409
- Testing
- Olverembatinib, Investigator's choice of TKI
- Where
- 90 sites in United States, Australia and 10 more
- Volunteers
- 350 people
- Sponsor
- Ascentage Pharma Group Inc.
B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML
This phase I/II trial studies the side effects and best dose of bosutinib when given together with inotuzumab ozogamicin and to see how well it works in treating patients with acute lymphoblastic leukemia or chronic myeloid…
- Conditions
- B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Blasts More Than 5 Percent of Bone Marrow Nucleated Cells, CD22 Positive
- Trial name
- NCT02311998
- Testing
- Bosutinib, Inotuzumab Ozogamicin
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- M.D. Anderson Cancer Center
Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia
Study to Evaluate Nilotinib in Adult Patients With Imatinib-resistant or Imatinib-intolerant Chronic Myelogenous Leukemia (CML), or Relapse/Refractory Ph+ Acute Lymphoblastic Leukemia (ALL) (Extension Study)
This study will investigate if nilotinib provides an improved safety and efficacy profile over that seen in patients receiving Imatinib.
- Trial name
- NCT01279473
- Testing
- Nilotinib
- Where
- Japan
- Volunteers
- 42 people
- Sponsor
- Novartis Pharmaceuticals
Lymphoblastic Leukemia, Acute
Tyrosine Kinase Inhibitors and Low Intensity Chemotherapy in Ph+ ALL
The use of imatinib in combination with chemotherapy is now considered as the gold standard for the treatment of Ph+ ALL. The complete remission (CR) rate is 90% versus 20% to 40% with chemotherapy alone.
- Trial name
- EWALL_OBS (NCT02888977)
- Where
- 3 sites in France
- Volunteers
- 100 people
- Sponsor
- Versailles Hospital
Philadelphia-Positive ALL, Acute Lymphoblastic Leukemia, in Relapse
Ponatinib in Adult Ph+ ALL Patients With MRD Positivity or Hematological Relapse
This is a phase II interventional trial to evaluate if the use of ponatinib, with or without chemotherapy, can induce a molecular remission in MRD-positive patients, in patients in hematologic and extra-hematologic relapse and in…
- Trial name
- NCT04475731
- Testing
- Ponatinib
- Where
- 22 sites in Italy
- Volunteers
- 67 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Leukemia, Myeloid, Chronic, Leukemia, Lymphocytic, Acute, L2
A Study of Dasatinib in Patients With Chronic Myelogenous Leukemia Who Are Resistant or Intolerant of Imatinib Mesylate
The purpose of this clinical research study is to provide dasatinib treatment to patients with advanced chronic myelogenous leukemia (CML) or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who no longer…
- Trial name
- NCT00298987
- Testing
- Dasatinib
- Where
- 35 sites in United States, Canada
- Volunteers
- 400 people
- Sponsor
- Bristol-Myers Squibb
Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia, Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia
CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant
This phase I/II trial studies the safety and toxicity of post-transplant treatment with donor T cells engineered to express a chimeric antigen receptor (CAR) targeting CD19 in patients who have had a matched related allogeneic…
- Conditions
- Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia, Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Diffuse Large Cell Lymphoma
- Trial name
- NCT01475058
- Testing
- allogeneic cytomegalovirus-specific cytotoxic T lymphocytes
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Fred Hutchinson Cancer Center
Acute Undifferentiated Leukemia, B-cell Adult Acute Lymphoblastic Leukemia
Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia
This phase I/II trial studies the side effects and best dose of alemtuzumab when given together with combination chemotherapy and to see how well it works in treating patients with untreated acute lymphoblastic leukemia.
- Conditions
- Acute Undifferentiated Leukemia, B-cell Adult Acute Lymphoblastic Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia, L1 Adult Acute Lymphoblastic Leukemia
- Trial name
- NCT00061945
- Testing
- allopurinol, cyclophosphamide, daunorubicin hydrochloride
- Where
- United States
- Volunteers
- 302 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma, Multiple Myeloma
Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY
The purpose of this research is to find the most effective and least toxic way to prevent GVHD after BMT.
- Conditions
- Lymphoma, Multiple Myeloma, Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT00809276
- Testing
- Busulfan, Fludarabine, Cytoxan
- Where
- 3 sites in United States
- Volunteers
- 92 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Leukemia
Dasatinib and Vorinostat in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia
RATIONALE: Dasatinib and vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving dasatinib together with vorinostat may kill more cancer cells.
- Trial name
- NCT00816283
- Testing
- dasatinib, vorinostat, cytogenetic analysis
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- City of Hope Medical Center
B Acute Lymphoblastic Leukemia, CD19 Positive
CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies
This phase I trial studies the side effects of CD19/CD22 chimeric antigen receptor (CAR) T cells when given together with chemotherapy and NKTR-255, and to see how well they work in treating patients with CD19 positive B acute…
- Conditions
- B Acute Lymphoblastic Leukemia, CD19 Positive, Minimal Residual Disease, Philadelphia Chromosome Positive
- Trial name
- NCT03233854
- Testing
- Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Fludarabine Phosphate
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Stanford University
Chronic Phase Chronic Myelogenous Leukemia, Accelerated Phase Chronic Myelogenous Leukemia
CALLS: CML and Ph+ALL Low Level Mutation Prevalence Survey
A multicenter, prospective cohort study of the mutation status of patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) who are being treated with first or…
- Conditions
- Chronic Phase Chronic Myelogenous Leukemia, Accelerated Phase Chronic Myelogenous Leukemia, Blastic Phase Chronic Myelogenous Leukemia, Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
- Trial name
- NCT03647215
- Where
- 33 sites in Ireland, United Kingdom
- Volunteers
- 427 people
- Sponsor
- Incyte Biosciences UK